Loading
Latest filing published 05 Nov 2025 for Terns Pharmaceuticals, Inc., €197k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jill M. Quigley is a declared insider at 2 companies (senior executive); the most frequent names are Terns Pharmaceuticals, Inc. and Passage BIO, Inc. Between 8 December 2021 and 4 November 2025, the trades on record add up to 8 filings.
On the market, this insider has only sold: 2 sales, €78k in total. Outside the open market, there are 2 share grants and 4 option exercises. In 2025 alone, the filings show no purchases and 1 sale.
On 5 November 2025 came the latest disclosure, an option exercise for €197k in Terns Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations